# Ignis Therapeutics

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/ignis-therapeutics

- Industry: Biotechnology
- Headquarters: Shanghai, China
- Total disclosed funding: $183M
- Latest round: Series A (Jan 20, 2023)
- Investors on record: 7

## About

Based in Shanghai, China and founded in 2020, Ignis Therapeutics is a developer of innovative therapies for the central nervous system. The company's CEO Dr. Aijing Long once serves as general manager of Sanofi. Ignis Therapeutics has a strategic cooperation with SK Biopharmaceuticals. In November 2021, the company raised USD 180 million in series A funding.

The company's product Cenobamate is an innovative antiepileptic drug. And Solrimfetol is used to treat excessive daytime sleepiness (EDS) caused by narcolepsy or obstructive sleep apnea (OSA). Ignis Therapeutics also has licensing rights to six innovative drugs including Cenobamate and Solriamfetol.

## Funding rounds

- Series A, Jan 20, 2023, $2.8M — HBM Partners
- Series A, Nov 11, 2021, $180M — HBM Partners, Mubadala Investment Company, KB Investment, Goldman Sachs Asset Management, W.T.T. Investment, 6 Dimensions Capital, Ruentex Group

## Investors

- HBM Partners (https://capitalatlas.ai/funds/hbm-partners) — Series A
- Mubadala Investment Company — Series A
- KB Investment (https://capitalatlas.ai/funds/kb-investment) — Series A
- Goldman Sachs Asset Management (https://capitalatlas.ai/funds/goldman-sachs-asset-management) — Series A
- W.T.T. Investment — Series A
- 6 Dimensions Capital (https://capitalatlas.ai/funds/6-dimensions-capital) — Series A
- Ruentex Group (https://capitalatlas.ai/funds/ruentex-group) — Series A